Abstract
Background: The glycolytic pathway plays an important role in tumor cells. Triosephosphate isomerase (TIM) catalyzes the reversible isomerization of D-glyceraldehyde-3-phosphate (GAP) to dihydroxyacetone phosphate (DHAP) in the glycolysis. Proteomics of a human prostate adenocarcinoma cell line revealed the presence of the G233D TIM variant, a new allelic type whose biochemical properties have not been reported [1].
Objective: Provide the first biochemical and biophysical characterization of the allelic variant G233D of TIM.
Methods: The Michaelis-Menten curves using both substrates of TIM were obtained. Also the effect of the competitive inhibitor phosphoenolpyruvate (PEP) was assessed in presence of GAP and DHAP. The thermal stability in absence and presence of PEP was analyzed by circular dichroism spectroscopy. For comparison purposes, all the measurements were carried out on the wild type TIM and variant G233D.
Results: The G233D variant exhibited a kcat value 4-fold lower than that of the WT enzyme in the GAP isomerization to DHAP, which is the reverse reaction of the glycolytic pathway. The G233D variant exhibited Ki and IC50 values of 120 μM and 356 μM in the presence of several concentrations of GAP and 0.3 mM DHAP, respectively. These inhibition parameters are similar to those exhibited by the WT enzyme. The thermal unfolding cooperativity of G233D variant was significantly increased upon PEP binding, suggesting that the ligand-bound enzyme was trapped in a rigid conformation.
Conclusion: We suggest that the flow of GAP through glycolysis could be enhanced by the decreased activity of the G233D variant in the formation of DHAP.
Keywords: Allelic variant, glyceraldehyde-3-phosphate, glycolysis, human prostate cancer, phosphoenolpyruvate, triosephosphate isomerase.
Graphical Abstract
Current Enzyme Inhibition
Title:Characterization of a New Allelic Variant of Triosephosphate Isomerase from the LNCaP Human Prostate Cancer Cell Line: Enzyme Inhibition and Spectroscopic Studies
Volume: 13 Issue: 3
Author(s): Valeria Guzmán-Luna, Leticia Olvera-Rodríguez, Peniel Bustamante-Villalobos and Gloria Saab-Rincón*
Affiliation:
- Departamento de Ingeniería Celular y Biocatálisis, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Apdo. Postal 510-3, 62250 Cuernavaca, Mor,Mexico
Keywords: Allelic variant, glyceraldehyde-3-phosphate, glycolysis, human prostate cancer, phosphoenolpyruvate, triosephosphate isomerase.
Abstract: Background: The glycolytic pathway plays an important role in tumor cells. Triosephosphate isomerase (TIM) catalyzes the reversible isomerization of D-glyceraldehyde-3-phosphate (GAP) to dihydroxyacetone phosphate (DHAP) in the glycolysis. Proteomics of a human prostate adenocarcinoma cell line revealed the presence of the G233D TIM variant, a new allelic type whose biochemical properties have not been reported [1].
Objective: Provide the first biochemical and biophysical characterization of the allelic variant G233D of TIM.
Methods: The Michaelis-Menten curves using both substrates of TIM were obtained. Also the effect of the competitive inhibitor phosphoenolpyruvate (PEP) was assessed in presence of GAP and DHAP. The thermal stability in absence and presence of PEP was analyzed by circular dichroism spectroscopy. For comparison purposes, all the measurements were carried out on the wild type TIM and variant G233D.
Results: The G233D variant exhibited a kcat value 4-fold lower than that of the WT enzyme in the GAP isomerization to DHAP, which is the reverse reaction of the glycolytic pathway. The G233D variant exhibited Ki and IC50 values of 120 μM and 356 μM in the presence of several concentrations of GAP and 0.3 mM DHAP, respectively. These inhibition parameters are similar to those exhibited by the WT enzyme. The thermal unfolding cooperativity of G233D variant was significantly increased upon PEP binding, suggesting that the ligand-bound enzyme was trapped in a rigid conformation.
Conclusion: We suggest that the flow of GAP through glycolysis could be enhanced by the decreased activity of the G233D variant in the formation of DHAP.
Export Options
About this article
Cite this article as:
Guzmán-Luna Valeria, Olvera-Rodríguez Leticia, Bustamante-Villalobos Peniel and Saab-Rincón Gloria*, Characterization of a New Allelic Variant of Triosephosphate Isomerase from the LNCaP Human Prostate Cancer Cell Line: Enzyme Inhibition and Spectroscopic Studies, Current Enzyme Inhibition 2017; 13 (3) . https://dx.doi.org/10.2174/1573408012666160906110330
DOI https://dx.doi.org/10.2174/1573408012666160906110330 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Newly Recognized Receptors for Vitamin D Metabolites
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) DNA Microarray-Based Gene Expression Profiling in Cancer: Aiding Cancer Diagnosis, Assessing Prognosis and Predicting Response to Therapy
Current Pharmacogenomics Mitochondrial Drug Targets in Cell Death and Cancer
Current Pharmaceutical Design Impact of Oncogenic Protein Tyrosine Phosphatases in Cancer
Anti-Cancer Agents in Medicinal Chemistry Patent Selections:
Recent Patents and Topics on Imaging (Discontinued) The Sigma Receptor: Evolution of the Concept in Neuropsychopharmacology
Current Neuropharmacology Editorial [Hot topic: Prostate Cancer Therapy (Guest Editors: N. Sharifi and J.B. Aragon-Ching)]
Anti-Cancer Agents in Medicinal Chemistry Roles of Natural Compounds from Medicinal Plants in Cancer Treatment: Structure and Mode of Action at Molecular Level
Medicinal Chemistry The Potential of Modulating Small RNA Activity In Vivo
Mini-Reviews in Medicinal Chemistry Conotoxins-New Vistas for Peptide Therapeutics
Current Pharmaceutical Design Effects of Long-Term Intraperitoneal Injection of Thyrotropin-Releasing Hormone (TRH) on Aging- and Obesity-Related Changes in Body Weight, Lipid Metabolism, and Thyroid Functions
Current Aging Science ADAM17 as a Therapeutic Target in Multiple Diseases
Current Pharmaceutical Design Peptides and Small Molecules Targeting the Plasminogen Activation System: Towards Prophylactic Anti-Metastasis Drugs for Breast Cancer
Recent Patents on Anti-Cancer Drug Discovery Menin, Histone H3 Methyltransferases, and Regulation of Cell Proliferation: Current Knowledge and Perspective
Current Molecular Medicine Synthesis and Biological Evaluation of New imidazo[1,2-a]pyridine Derivatives as Selective COX-2 Inhibitors
Letters in Drug Design & Discovery The Crosstalk Between the Matrix Metalloprotease System and the Chemokine Network in Acute Myeloid Leukemia
Current Medicinal Chemistry Resveratrol-Mediated Reversal of Tumor Multi-Drug Resistance
Current Drug Metabolism Advances in Transient Receptor Potential Vanilloid-2 Channel Expression and Function in Tumor Growth and Progression
Current Protein & Peptide Science Macrocyclic Histone Deacetylase Inhibitors
Current Topics in Medicinal Chemistry High-density Lipoprotein, Vascular Risk, Cancer and Infection: A Case of Quantity and Quality?
Current Medicinal Chemistry